Cell News and Research

RSS

Irvine Scientific receives CE mark for its ART products

Irvine Scientific, a leader in Assisted Reproductive Technologies (ART) announced today that it has received CE mark for a full range of its media designed for ART: Complete P-1® Medium with DSS™, Blastocyst Freeze Media, Blastocyst Thaw Media, Embryo Freeze Media, Embryo Thaw Media, Complete Early Cleavage Medium® (ECM®) with DSS™ and Complete MultiBlast Medium® with DSS™, Sperm Washing Medium, Sperm Maintenance Medium w/ HSA, 7% PVP w/ HSA, 10% PVP w/ HSA.

5 Jan 2010

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have discovered a new agent that might inhibit the infectivity of HIV. The agent, surfen, impairs the action of a factor in semen that greatly enhances the viral infection.

5 Jan 2010

Jamming bacterial communication may improve chronic wound care

Listening in on bacterial conversations could be the solution for improving chronic wound care, says a team of researchers at Binghamton University, State University of New York. Their findings have been published in the Journal of Applied Microbiology.

5 Jan 2010

A 'cocktail' to kill cancerous tumors

A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors.

5 Jan 2010

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Boston Scientific Corporation today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study is designed to evaluate real-world clinical outcomes data for the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient®, a new antiplatelet medication. Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo, Inc., manufacturers of Effient, which was recently approved by the U.S. Food and Drug Administration (FDA).

4 Jan 2010

Cord Blood America signs Letter of Intent to process and store cord blood specimens for BioCells

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has signed a Letter of Intent to process and store cord blood specimens for BioCells, Inc., headquartered in Argentina, and its affiliates in Peru, Colombia, Bolivia, Panama and Puerto Rico.

4 Jan 2010

Scientists uncover an important link between inflammation and breast cancer stem cells

Scientists at the University of Michigan Comprehensive Cancer Center have uncovered an important link between inflammation and breast cancer stem cells that suggests a new way to target cells that are resistant to current treatments.

4 Jan 2010

Discovery of key process in bacterial infection could lead to new drug targets to prevent infection

Bacteria can swim, propelling themselves through fluids using a whip-like extension called a flaggella. They can also walk, strolling along solid surfaces using little fibrous legs called pili. It is this motility that enable some pathogenic bacteria to establish the infections - such as meningitis - that cause their human hosts to get sick or even die.

4 Jan 2010

Cardiogenesis submits an IDE for its PHOENIX System

Cardiogenesis Corporation, today announced that it has submitted an IDE (Investigational Device Exemption) to the Food and Drug Administration to initiate a safety and feasibility trial for its PHOENIX System in patients with refractory angina. The PHOENIX handpiece is the first device specifically designed to allow physician-directed tissue stimulation and injections of biologic or pharmacologic agents to pre-determined areas of myocardium.

4 Jan 2010

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.

4 Jan 2010

ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).

4 Jan 2010

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

BioInvent International AB announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.

4 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Research may point to more effective therapeutic targets for prion diseases

Scientists from The Scripps Research Institute have determined for the first time that prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, are capable of Darwinian evolution.

4 Jan 2010

Attorney General implores Congress to remove Nebraska provision from federal health care legislation

Attorney General Tom Corbett has joined 11 of his fellow attorneys general urging the leaders of Congress to delete the Nebraska provision from the pending federal health care legislation.

4 Jan 2010

Novelos continues NOV-002 Phase 3 combination trial for lung cancer

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.

4 Jan 2010

Scientists identify genetic marker to diagnose DFTD

An international team of scientists led by a Cold Spring Harbor Laboratory (CSHL) investigator has discovered that the deadly facial tumors decimating Australia's Tasmanian devil population probably originated in Schwann cells, a type of tissue that cushions and protects nerve fibers.

4 Jan 2010

UI cell membrane protein study may lead to new methods of tracking metastasizing cancer cells

With the discovery of a new type of chemical modification on an important muscle protein, a University of Iowa study improves understanding of certain muscular dystrophies and could potentially lead to new treatments for the conditions.

4 Jan 2010

HIRU and HTDS announce finalization of MindUp BioResearch Division sale

This is a joint press release of Hiru Corporation (HIRU) and Hard to Treat Diseases (HTDS) - The two companies are pleased to announce the finalization and completion of the purchase and sale of the MindUp BioResearch Division. Details of the transaction completed on cash and stock basis can be found at the Pink Sheets web site www.pinksheets.com under the "filings" tab.

3 Jan 2010

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

Anika Therapeutics, Inc. today announced that it has acquired Fidia Advanced Biopolymers, s.r.l. (“FAB”), a wholly-owned subsidiary of privately held Italian pharmaceutical company, Fidia Farmaceutici S.p.A. FAB provides hyaluronic acid-based (“HA”) products in several therapeutic areas including for the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.

3 Jan 2010

Cell News and Research

Irvine Scientific receives CE mark for its ART products

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

Jamming bacterial communication may improve chronic wound care

A 'cocktail' to kill cancerous tumors

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Cord Blood America signs Letter of Intent to process and store cord blood specimens for BioCells

Scientists uncover an important link between inflammation and breast cancer stem cells

Discovery of key process in bacterial infection could lead to new drug targets to prevent infection

Cardiogenesis submits an IDE for its PHOENIX System

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Research may point to more effective therapeutic targets for prion diseases

Attorney General implores Congress to remove Nebraska provision from federal health care legislation

Novelos continues NOV-002 Phase 3 combination trial for lung cancer

Scientists identify genetic marker to diagnose DFTD

UI cell membrane protein study may lead to new methods of tracking metastasizing cancer cells

HIRU and HTDS announce finalization of MindUp BioResearch Division sale

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News